Login
Companies $LSTA
$1.10 +$0.01 (0.92%) After hours
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC.

lisata.com

What Do They Do?

Develops certepetide, an investigational drug intended to help anti-cancer medicines enter solid tumors, for pharmaceutical developers and research collaborators.

How Do They Make Money?

Pharmaceutical partners pay Lisata upfront fees for licenses; its Qilu agreement also provided for milestone payments and royalties on licensed-product sales.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners license certepetide rights from Lisata; past agreements included Qilu in Greater China and Kuva under an exclusive license and collaboration agreement.

Do Revenues Turn Into Profits?

No. It lost $16.6M in FY2025.

Operating income, FY2025
−10711% of revenue
▲ +19% (Loss) vs FY2024 (−$22.4M, −2241%)
Net income, FY2025
−9756% of revenue
▲ +17% (Loss) vs FY2024 (−$20M, −1999%)
Free cash flow, FY2025
−9398% of revenue
▲ +17% (Loss) vs FY2024 (−$19.4M, −1936%)

How Are They Changing?

Since the FY2024 annual report
  • Sep 17, 2026 Lisata acquired Marea Therapeutics The combined company said it would focus on cardioendocrine candidates MAR001/005 and MAR002; a concurrent private placement was expected to raise $225 million.
  • Jul 24, 2026 Kuva merger agreement terminated after the buyer failed to secure financing Kuva was obligated to pay a $2,000,000 termination fee, and the board planned to assess strategic options.

From cell therapies to certepetide The older report centered on patient-derived cell therapies for ischemic diseases; the latest centers on certepetide, a peptide intended to help anti-cancer drugs enter solid tumors.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support